Psoriasis experts discuss updates with IL-17 inhibitors and how they have changed the treatment landscape for plaque psoriasis.
EP. 1: Pathogenesis of Plaque Psoriasis
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss pathogenesis of plaque psoriasis and new emerging targets.
EP. 2: Treatment Selection for Plaque Psoriasis
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.
EP. 3: Approaching Plaque Psoriasis Treatment Based on Comorbidities
Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.
EP. 4: Role of IL-17 Inhibitor Durability in Plaque Psoriasis
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.
EP. 5: Using Bimekizumab to Manage Plaque Psoriasis
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.
EP. 6: Managing Candidiasis Associated With IL-17 Inhibitors in Plaque Psoriasis
Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.
EP. 7: Gaps in Plaque Psoriasis Care
Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis.
EP. 8: Future of Plaque Psoriasis Management
Drs Mark G. Lebwohl and Alice B. Gottlieb discuss future expectations in the treatment of plaque psoriasis.